Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VALEANT PHARMACEUTICALS INTL INC T.VRX

"Valeant Pharmaceuticals is a global specialty pharmaceutical firm with a focus on branded products for the dermatology, gastrointestinal, and ophthalmology markets. The firm also has a branded generics business that operates primarily in Latin America, Eastern Europe, and Asia."


TSX:VRX - Post by User

Post by Carlos66on Jun 09, 2016 8:42am
134 Views
Post# 24949689

re: its time to start paying dividends..really!

re: its time to start paying dividends..really! Wells Fargo's Donald Maris who (the only analyst that got it right on VRX from the beginning) initiated a sell signal in Feb/16, cut his target on VRX again to $17-22. underperform.

He stated...2020 debt may not be covered
             ...deal with Walgreens worse than anyone expected
             ...bankruptcy possible
             ...if they sell assets the income that is projected will go down & negate their assumptions
             ...if they sell assets they will start with the lesser assets which won't reduce debt very much

Jim Chanos said

Valeant was genius at gaming the system; that game is over.

'Chanos said Valeant’s downfall started as a number of top executives left the company. The short-seller said that one trouble sign in a company is when executives leave in tandem.

Chanos said "everybody" is using metrics that are "just as bad as Valeant's accounting ... I think that a lot of people are operating in this stock on the basis of false presumptions."

The whole idea was to buy things and then hike prices dramatically. The payers have woken up — that is the difference here. Valeant was genius at gaming the system; that game is over ... This was financial engineering, this was not pharmaceutical development.

Chanos said that its stock is worth zero minus the few acquisitions the company made in the past few years.

Game over. Going to zero.

PS...I don't own any stock nor am I short the stock.

carlos

 

<< Previous
Bullboard Posts
Next >>